Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial

Autor: Robert S. Lindsay, Corinne D. B. Love, Rebecca M. Reynolds, Claire I. Alexander, Ben Stenson, Sonia Whyte, Jennifer L Bell, Jessica Penneycard, Fiona Mackenzie, Mark W. J. Strachan, Ed Juszczak, Fiona C. Denison, Jane E. Norman

Publikováno v: BMC Pregnancy and Childbirth
Reynolds, R M, Denison, F C, Juszczak, E, Bell, J M L, Penneycard, J, Strachan, M W J, Lindsay, R S, Health, S C F, Love, C D B, Whyte, S, Mackenzie, F, Stenson, B & Norman, J E 2017, ' Glibenclamide and metfoRmin versus stAndard Care in gEstational diabeteS (GRACES): a feasibility open label randomised trial ', BMC pregnancy and childbirth . https://doi.org/10.1186/s12884-017-1505-3
BMC Pregnancy and Childbirth, Vol 17, Iss 1, Pp 1-9 (2017)

Background Metformin is widely used to treat gestational diabetes (GDM), but many women remain hyperglycaemic and require additional therapy. We aimed to determine recruitment rate and participant throughput in a randomised trial of glibenclamide com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ae64b4ed01347244f283b11820eb16c
https://pubmed.ncbi.nlm.nih.gov/28938877